海正药业：HS387片获美国FDA新药临床试验批准

Core Viewpoint - The company has received FDA approval for clinical trials of its self-developed drug HS387, a selective KIF18A inhibitor intended for the treatment of advanced solid tumors, marking a significant step in its drug development pipeline [1] Group 1: Drug Development - The HS387 drug has been approved for clinical trials in the United States, following prior approval from the National Medical Products Administration in China [1] - Currently, multiple KIF18A inhibitors are in clinical development stages globally, but none have been approved for market release yet [1] Group 2: Business Impact - The approval for clinical trials is expected to have a limited short-term impact on the company's business operations, as further clinical trials are required before any potential market launch [1] - Investors are advised to remain cautious regarding potential risks associated with the drug's development process [1]